Publicacións en colaboración con investigadores/as de Hospital General Universitario de Valencia (9)

2023

  1. Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer

    Thrombosis Research, Vol. 232, pp. 133-137

  2. Immune checkpoint inhibitor-associated thrombosis in patients with bladder and kidney cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group

    Clinical and Translational Oncology, Vol. 25, Núm. 10, pp. 3021-3031

  3. Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer

    New England Journal of Medicine, Vol. 389, Núm. 6, pp. 504-513

  4. Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)

    Journal of Clinical Oncology, Vol. 41, Núm. 28, pp. 4478-4485

2022

  1. Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics

    BMC Cancer, Vol. 22, Núm. 1

  2. Measures to evaluate quality of care in renal cancer: results of a Delphi study in Spain

    Clinical and Translational Oncology, Vol. 24, Núm. 3, pp. 495-502

2021

  1. PD-L1 testing and clinical management of newly diagnosed metastatic non-small cell lung cancer in Spain: MOREL study

    Lung Cancer Management, Vol. 10, Núm. 4

  2. Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data

    BMC Cancer, Vol. 21, Núm. 1

2016

  1. Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study

    BMC Cancer, Vol. 16, Núm. 1